Литература. 
Оценка клинической эффективности ивабрадина у пациентов со стабильной стенокардией

1. Серцево-судинні захворювання. Класифікація, стандарти діагностики та лікування кардіологічних хвори / За ред. В. М. Коваленка, М.І. Лутая, Ю.М. Сіренка. — К., 2007. — С. 59−67.

2. ACC, AHA, ACP-ASIM. Chronic Stable Angina. — Guidelines, 1999. — P. 23.

3. Beere P., Glagov S., Zarins C. Retarding effect of lowered heart rate on coronary atherosclerosis // Science. — 1984. — Vol. 226. — P. 180−182.

4. Bois P., Bescond J., Renaudon B., Lenfant J. Mode of action of bradycardic agent, S16257, on ionic currents of rabbit sinoatrial node cells // Brit. J. Pharmacol. — 1996. — Vol. 118. — P. 1051−1057.

5. Borer J., Fox K., Jaillon P., Lerebours G. Ivabradine Investiga-tors Group. Anti-anginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blinded, multicentered, placebo controlled trial // Circulation. — 2003. — Vol. 107. — P. 817−823.

6. Colin O., Ghaleh B., Hittinger L. et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise // Amer. J. Physiol. Heart Circ. Physiol. — 2002. — Vol. 282. — P. 672−679.

7. Demontis G., Longoni B., Barcaro U., Cervetto L. Properties and functional roles of hyperpolarization-gated currents in guinea pig retinal rods // J. Physiol. — 1999. — Vol. 515. — P. 813−828.

8. DiFrancesco D. Characterization of single pacemaker channels in cardiac sino-atrial node cells // Nature. — 1986. — Vol. 324. — P. 470−473.

9. DiFrancesco D. The contribution of the «pacemaker» current (If) to generation of spontaneous activity in rabbit sino-atrial node myocytes // J. Physiol. — 1991. — Vol. 34. — P. 23−40.

10. DiFrancesco D., Camm A. Heart rate lowering by specific and selective if current inhibition with ivabradin // Drugs. — 2004. — Vol. 64, № 16. — P. 1757−1765.

11. Fogari R., Zoppi A., Corradi L. et al. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study // Amer. J. Hypertension. — 1998. — Vol. 11. — P. 1244−1247.

12. Fox K., Ferrari R., Tendera M. et al.; BEAUTIFUL Steering Committee (2006). Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I (f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study // Amer. Heart J. — 2006. — Vol. 152. — P. 860−866.

13. Fox K., Garcia M.A., Ardissino D. et al. Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG) Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology // Eur. Heart J. — 2006. — Vol. 27. — P. 1341−1381.

14. Guth B., Heusch G., Seitelberger R., Ross J. Mechanisms of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs // Circ. Res. — 1987. — Vol. 60. — P. 738−746.

15. Kjekshus J. Importance of heart rate in determing beta-blocker efficacy in acute and long-term myocardial infarction intervention trials // Amer. J. Cardiol. — 1986. — Vol. 57. — P. 43−49.

16. Ko D., Hebert P., Coffey C. et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction // JAMA. — 2002. — Vol. 288. — P. 351−357.

17. Ruzyllo W., Ford I., Tendera M. et al. Antianginal and anti-ischemic effects of If current inhibitor ivabradine compared to amlodipine as monotherapy in patients with chronic stable angina: a 3-month randomized, controlled, double-blind, multicenter trial // Drugs. — 2007. — Vol. 67, № 3. — P. 393−405.

18. Simon L., Ghaleh B., Puybasset L. et al. Coronary and hemodynamic effects of S16257, a new bradycardic agent, in resting and exercising conscious dogs // J. Pharmacol. Exp. Ther. — 1995. — Vol. 275. — P. 659−666.

19. Tafreshi M., Weinacher A. Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma // Pharmacotherapy. — 1999. — Vol. 19. — P. 974−978.

20. Tardiff J., Ford I., Tendera M. for the INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina // Eur. Heart J. — 2005. — Vol. 26. — P. 2529−2536.

21. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction // New Engl. J. Med. — 1981. — Vol. 304. — P. 801−807.

22. Thollon C., Cambarrat C., Vian J. et al. Electrophysiological effects of S 16 257, a novel sino-atrial node pharmacol modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49 // Brit. J. Pharmacol. — 1994. — Vol. 112. — P. 37−42.